Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant for L-dopa Induced Dyskinesias in PD
NCT01385592Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of mavoglurant in levodopa-induced dyskinesia (LID), sponsored by Novartis. Started Nov 2011; status: completed.
02
Drugs
mavoglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT01385592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01385592.